Description

Qiagen Shares Surge 7.3% As Buyout Race Intensifies After Failed Thermo Fisher Deal!

Qiagen has suddenly moved to the center of the diagnostics M&A conversation after reports suggested that discussions with at least one potential buyer had advanced, sending the stock up 7.3%. The latest speculation builds on months of takeover interest surrounding the molecular diagnostics company, with TPG, Bain Capital, KKR, EQT, and Advent all reportedly evaluating opportunities involving Qiagen. The development comes after the company began working with Moelis & Co. and Goldman Sachs on a strategic review earlier in 2026. Importantly, takeover interest is resurfacing six years after Thermo Fisher abandoned its attempt to acquire Qiagen, despite raising its offer from €39 to €43 per share following shareholder resistance. This time, potential buyers are looking at a business with strong margins, significant cash generation, growing laboratory automation exposure, recurring consumables demand, digital PCR momentum, and an expanding biomedical data operation.